# Incidence of marginal ulcer after one anastomosis gastric bypass versus Roux-en-Y gastric bypass: a comparative study

**Authors:** Ahmed Abdelsalam, Ahmed Fahmy, Ahmed Saqr, Sherkawi Elsayed, Ahmed Mohamed Salah Eldden Othman Elansary

PMC · DOI: 10.1186/s12893-026-03559-y · BMC Surgery · 2026-02-20

## TL;DR

This study compares the risk of marginal ulcers after two types of gastric bypass surgeries and finds that one type has a significantly lower risk.

## Contribution

The study provides new comparative evidence on marginal ulcer incidence between one-anastomosis and Roux-en-Y gastric bypass surgeries.

## Key findings

- Marginal ulcers occurred in 19.4% of RYGB patients versus 3.2% in OAGB patients.
- RYGB surgery and diabetes were significant predictors of marginal ulcers after adjusting for confounding factors.

## Abstract

Although Roux-en-Y gastric bypass (RYGB) has proven to be a safe and effective choice for long-standing weight loss, associated complications have been described. Among them, marginal ulcer (MU) has been recognized as one of the more significant postoperative complications. One-anastomosis gastric bypass (OAGB) has currently been the third most common procedure overall in the world. Similar to RYGB, concerns have emerged for MU risk after OAGB. This study aimed to compare the incidence of MU after RYGB versus OAGB.

This is a cross-sectional study that included 62 adult patients who underwent RYGB or OAGB and were followed up for a period of two years. The included patients underwent a complete general examination and upper gastrointestinal endoscopy.

The prevalence of MU in RYGB patients was 19.4%, whereas in OAGB patients, it was markedly lower at 3.2%, with a statistically significant difference (p = 0.045). In the multivariate analysis, the presence of diabetes and the type of surgery (RYGB) were significant predictors for MU.

Marginal ulcers occurred at a relatively high rate after bypass surgery. OAGB demonstrated a significantly lower incidence of MUs compared to RYGB. Type 2 diabetes mellitus and the RYGB procedure were significant predictors of MU after adjusting for the confounding factors.

The online version contains supplementary material available at 10.1186/s12893-026-03559-y.

## Linked entities

- **Diseases:** Type 2 diabetes mellitus (MONDO:0005148)

## Full-text entities

- **Genes:** GAST (gastrin) [NCBI Gene 2520] {aka GAS}
- **Diseases:** Metabolic Disorders (MESH:D008659), fistula (MESH:D005402), erythema (MESH:D004890), gastro-gastric fistula (MESH:D005747), ulcerogenic (MESH:D015408), intra-abdominal bleeding (MESH:D000082122), vomiting (MESH:D014839), hematemesis (MESH:D006396), OAGB (MESH:D013272), T2DM Type II Diabetes Mellitus (MESH:D003924), bleeding (MESH:D006470), mucosal damage (MESH:D052016), Obesity (MESH:D009765), abdominal symptoms (MESH:D000007), autoimmune conditions (MESH:D001327), epigastric symptoms (MESH:C537170), Infection (MESH:D007239), mucosal irritation (MESH:D001523), MU (MESH:D010437), Diabetes Mellitus (MESH:D003920), microangiopathy (MESH:D014652), ischemic (MESH:D002545), EWL (MESH:D015431), Ulcer (MESH:D014456), DM (MESH:D009223), gastrointestinal symptoms (MESH:D012817), reflux (MESH:D005764), dyslipidemia (MESH:D050171), Hypertension (MESH:D006973), epigastric pain (MESH:D010146), melena (MESH:D008551)
- **Chemicals:** prostaglandin (MESH:D011453), OAGB (-), bile acids (MESH:D001647)
- **Species:** Helicobacter pylori (species) [taxon 210], Homo sapiens (human, species) [taxon 9606]

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12933895/full.md

## References

1 references — full list in the complete paper: https://tomesphere.com/paper/PMC12933895/full.md

---
Source: https://tomesphere.com/paper/PMC12933895